Dr Nuria Marquez Almuina

2025

• Knapper, S. et al. 2025. CPX-351 versus daunorubicin, cytarabine plus gemtuzumab ozogamicin in older adults with non-adverse risk AML: NCRI AML18 trial. Blood (10.1182/blood.2025031006)
• Russell, N. H. et al., 2025. Treatment intensification with either fludarabine, AraC, G-CSF and idarubicin, or cladribine plus daunorubicin and AraC on the basis of residual disease status in older patients With AML: Results From the NCRI AML18 Trial. Journal of Clinical Oncology 43 (6), pp.694-704. (10.1200/JCO.24.00259)

2022

• Freeman, S. D. et al., 2022. A randomized comparison of the fractionated versus single dose schedule of Gemtuzumab Ozogamicin at induction with determinants of benefit for older AML patients: UK NCRI AML18 trial results. Blood 140 (S1), pp.532-533. (10.1182/blood-2022-162245)

2013

• Errington, R. J. et al. 2013. Time-lapse microscopy approaches to track cell cycle and lineage progression at the single-cell level. Current Protocols in Cytometry 64 (12.4)(10.1002/0471142956.cy1204s64)
• Hole, P. S. et al. 2013. Overproduction of NOX-derived ROS in AML promotes proliferation and is associated with defective oxidative stress signaling. Blood 122 (19), pp.3322-3330. (10.1182/blood-2013-04-491944)

2008

• Tiffen, P. et al., 2008. A dual role for Oncostatin M signalling in the differentiation and death of mammary epithelial cells in vivo. Molecular Endocrinology 22 (12), pp.2677-2688. (10.1210/me.2008-0097)

2007

• Smith, P. J. et al. 2007. Mitotic bypass via an occult cell cycle phase following DNA topoisomerase II inhibition in p53 functional human tumor cells. Cell Cycle 6 (16), pp.2071-2081. (10.4161/cc.6.16.4585)

2004

• Marquez, N. et al. 2004. Microtubule stress modifies intra-nuclear location of Msh2 in mouse embryonic fibroblasts. Cell Cycle 3 , pp.662-671.

2003

• Marquez, N. et al. 2003. Single cell tracking reveals that Msh2 is a key component of an early-acting DNA damage-activated G2 checkpoint. Oncogene 22 (48), pp.7642-7648. (10.1038/sj.onc.1206876)